Journal
CIRCULATION
Volume 128, Issue 9, Pages 970-981Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCULATIONAHA.113.001746
Keywords
calcium-calmodulin-dependent protein kinase type 2; heart failure; hypertrophy; protein kinases; sarcoplasmic reticulum
Funding
- German Heart Foundation/German Foundation of Heart Research
- Deutsche Forschungsgemeinschaft [SFB 1002]
- Deutsche Forschungsgemeinschaft through a Heisenberg grant [MA 1982/4-2]
- Fondation Leducq Award
- German Cardiac Society (DGK)
Ask authors/readers for more resources
Background Sarcoplasmic reticulum (SR) Ca2+ leak through ryanodine receptor type 2 (RyR2) dysfunction is of major pathophysiological relevance in human heart failure (HF); however, mechanisms underlying progressive RyR2 dysregulation from cardiac hypertrophy to HF are still controversial. Methods and Results We investigated healthy control myocardium (n=5) and myocardium from patients with compensated hypertrophy (n=25) and HF (n=32). In hypertrophy, Ca2+/calmodulin-dependent protein kinase II (CaMKII) and protein kinase A (PKA) both phosphorylated RyR2 at levels that were not different from healthy myocardium. Accordingly, inhibitors of these kinases reduced the SR Ca2+ leak. In HF, however, the SR Ca2+ leak was nearly doubled compared with hypertrophy, which led to reduced systolic Ca2+ transients, a depletion of SR Ca2+ storage and elevated diastolic Ca2+ levels. This was accompanied by a significantly increased CaMKII-dependent phosphorylation of RyR2. In contrast, PKA-dependent RyR2 phosphorylation was not increased in HF and was independent of previous -blocker treatment. In HF, CaMKII inhibition but not inhibition of PKA yielded a reduction of the SR Ca2+ leak. Moreover, PKA inhibition further reduced SR Ca2+ load and systolic Ca2+ transients. Conclusions In human hypertrophy, both CaMKII and PKA functionally regulate RyR2 and may induce SR Ca2+ leak. In the transition from hypertrophy to HF, the diastolic Ca2+ leak increases and disturbed Ca2+ cycling occurs. This is associated with an increase in CaMKII- but not PKA-dependent RyR2 phosphorylation. CaMKII inhibition may thus reflect a promising therapeutic target for the treatment of arrhythmias and contractile dysfunction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available